What top creators are saying about Agenus Inc.(AGEN)
Clinical-stage immuno-oncology company.
5 AI-extracted insights from 2 sources — podcasts, YouTube channels, and X/Twitter accounts.
Creator sentiment — last 30 days
Based on 3 scored insights about Agenus Inc..
The Take
Coverage was bearish: all three insights featured Martin Shkreli or a related account describing Agenus Inc. (AGEN) as a short or criticizing the company. The central thesis was that price swings reflect trading flows and short covering rather than improving company-specific information.
Bear Case
- Company quality: Shkreli characterized Agenus as a poor-quality biotech and said he viewed it as a short (Martin Shkreli).
- Trading-flow volatility: Abrupt moves were attributed to hedge-fund deleveraging, position changes, or short covering—not new company information (Martin Shkreli, The Shkreli Pill).
- Downside exposure: Shkreli criticized the company and emphasized loss mitigation, while acknowledging rallies can happen without news (The Shkreli Pill).
Catalysts & Targets
- September 23 post noted +23% since July 1.
AI-generated summary. Not investment advice. Learn more.
Top creators covering Agenus Inc. (AGEN)
The 2 sources with the most insights about Agenus Inc. on Kazuha.
Latest insights about Agenus Inc. (AGEN)
AI-generated insights from podcasts, YouTube videos, and X posts — ordered by most recent.
Sunday, October 4, 2026
The speaker described being short and criticized the company, while noting that a sharp rise without news could be explained by fund deleveraging or short covering.
Thursday, September 24, 2026
The speaker said he was short and described the stock negatively, while attributing abrupt price swings to short covering and trading flows rather than new company information.
Wednesday, September 23, 2026
Shkreli called Agenus a poor-quality biotech and viewed it as a short. He attributed sharp moves in the stock to hedge-fund deleveraging and position changes, highlighting the risk of abrupt rallies or declines.
Tuesday, July 21, 2026
Host shorted AGEN twice during the episode, actively trading from the short side, momentum short.
Monday, July 13, 2026
Characterized as a 'dead biotech' with inferior mechanisms; price spike viewed as a dead cat bounce with a short opportunity toward the $3.00-$3.50 range.
Sunday, October 4, 2026
The speaker described being short and criticized the company, while noting that a sharp rise without news could be explained by fund deleveraging or short covering.
Thursday, September 24, 2026
The speaker said he was short and described the stock negatively, while attributing abrupt price swings to short covering and trading flows rather than new company information.
Wednesday, September 23, 2026
Shkreli called Agenus a poor-quality biotech and viewed it as a short. He attributed sharp moves in the stock to hedge-fund deleveraging and position changes, highlighting the risk of abrupt rallies or declines.
Tuesday, July 21, 2026
Host shorted AGEN twice during the episode, actively trading from the short side, momentum short.
Monday, July 13, 2026
Characterized as a 'dead biotech' with inferior mechanisms; price spike viewed as a dead cat bounce with a short opportunity toward the $3.00-$3.50 range.
Discussed alongside Agenus Inc. (AGEN)
Other assets that creators frequently mention in the same content as Agenus Inc..
Frequently asked
Are top creators bullish or bearish on Agenus Inc. (AGEN) right now?
Mostly bearish. In the last 30 days, 0 insights were bullish, 3 bearish, and 0 neutral about Agenus Inc. (AGEN) across 2 financial sources indexed on Kazuha.
Which podcasters and creators cover Agenus Inc. (AGEN) the most?
The most active sources covering Agenus Inc. (AGEN) on Kazuha are @realmartinshkreli, @theshkrelipill. Kazuha aggregates AI-extracted insights from podcasts, YouTube channels, and X/Twitter accounts.
How many insights about Agenus Inc. (AGEN) are on Kazuha?
Kazuha has indexed 5 AI-extracted insights about Agenus Inc. (AGEN) from 2 different sources. New insights are added whenever a covered creator publishes a new podcast episode, video, or post.
What other assets do creators discuss alongside Agenus Inc. (AGEN)?
Creators covering Agenus Inc. (AGEN) most frequently also discuss MU, SNDK, 000660, MRNA, IONQ. See the "Discussed alongside" section above for full asset pages.